The Wheel Strategy on ABBV (AbbVie): Full Setup, Sizing, and Real-World Numbers
What's in this guide
1. Why ABBV as a wheel candidate 2. The risks — post-Humira cliff + new drug pipeline 3. Strike selection on ABBV 4. Position sizing 5. A worked example — full cycle 6. Special considerations (dividend, earnings, FDA) 7. The mistakes wheelers make on ABBV 8. Next stepsABBV (AbbVie) is one of the largest US pharmaceutical companies, best known for Humira (now off-patent) and the successful transition to next-generation immunology drugs Skyrizi and Rinvoq. For wheelers, ABBV offers one of the highest dividend yields in mega-cap pharma (~3.5%), moderate IV, and post-Humira-cliff stabilization that de-risks a lot of the historical concern.
This guide walks through the complete wheel setup on ABBV — how to size, which strikes to sell, and what to expect through a real cycle.
1. Why ABBV as a wheel candidate
- High dividend (~3.5% yield) — one of the highest in mega-cap pharma
- Moderate IV (~20-28%) — decent premium capture
- Deep options liquidity — tight spreads
- Skyrizi + Rinvoq franchise — successful Humira replacement drugs
- Diversified portfolio — Botox (aesthetics), Vraylar (psychiatry), oncology assets
- Strong balance sheet — investment-grade credit, dividend Aristocrat trajectory
2. The risks — post-Humira cliff + new drug pipeline
- Humira revenue decline: continued biosimilar erosion (peak was ~$21B, now well below)
- Skyrizi/Rinvoq concentration: replacement franchise = concentration risk
- FDA approval risk: pipeline drug rejections can move shares
- Drug pricing regulation: Inflation Reduction Act pressures pricing
- Litigation: ongoing product liability lawsuits (industry standard)
3. Strike selection on ABBV
| Situation | Suggested delta | DTE |
|---|---|---|
| Normal conditions (IV rank 30-60) | 0.20-0.25 delta | 35-45 DTE |
| Elevated IV (drug news, IV rank 60+) | 0.15-0.20 delta | 35-45 DTE |
| Low IV (IV rank <30) | 0.20-0.25 delta | 30 DTE (shorter) |
| Before major FDA approval decisions | Wait for release | Post-news |
4. Position sizing
ABBV at $180 requires $18,000 per contract. Sizing rules:
- Max 20% of wheel capital in ABBV specifically
- Never let ABBV + LLY + MRK + PFE + JNJ exceed combined 30% (pharma concentration)
- Keep 30%+ cash cushion — FDA decisions can gap shares overnight
5. A worked example — full cycle
ABBV at $180, IV rank 45, no earnings for 40 days, no imminent FDA catalysts. You have $18,000 for this position:
| Day | Action | Result | Cumulative P/L |
|---|---|---|---|
| 0 | Sell 1 ABBV $175P, 35 DTE, 0.22 delta | Collect $340 premium | +$340 |
| 24 | Put worth $160 (53% profit). Buy to close. | Free capital. | +$180 net |
| 24 | Sell 1 ABBV $177P, 35 DTE, 0.22 delta | Collect $355 premium | +$535 |
| 59 | ABBV at $185 at expiration; put expired worthless. | Kept full $355. | +$535 |
$535 on $18,000 in 2 months = ~3% for cycle, ~18% annualized on premium alone. Add dividend when assigned (~$1.60/qtr per share = ~3.5% additional annual yield when holding).
6. Special considerations
A. Dividend
ABBV pays ~$6.20/year per share (~3.4% yield at $180). Quarterly dividends ~$1.55. Consistent dividend growth history since AbbVie's 2013 spinoff from Abbott. When holding shares, dividend income is approximately $155/quarter per contract — one of the highest in wheel-viable pharma names.
B. Earnings
ABBV reports quarterly. Moves can be 5-10% based on Humira decline trajectory, Skyrizi/Rinvoq growth rates, and full-year guidance. Standard rule: no new positions 7-10 days before earnings.
C. FDA + pipeline drug catalysts
FDA approval decisions on pipeline drugs (oncology, immunology, next-gen assets) can move ABBV 5-15% intraday. Track PDUFA dates for major decisions; reduce size 3-5 days before major FDA news.
7. The mistakes wheelers make on ABBV
Mistake #1: Still worrying about Humira cliff
The Humira patent cliff (2023) is now in the rearview mirror. Skyrizi + Rinvoq have successfully offset the revenue decline. Wheelers who overweight this concern miss the opportunity.
Mistake #2: Overallocating to pharma
ABBV + LLY + MRK + PFE + JNJ correlate on sector news. Cap combined pharma at 30% of wheel capital.
Mistake #3: Ignoring Skyrizi/Rinvoq concentration
The two replacement drugs are now 30%+ of revenue. Any competitive threat to either would matter. Watch competitive drug approvals.
8. Next steps
- Verify ABBV fits your account — $18,000 per contract, max 20% of wheel capital
- Use 0.20-0.25 delta, 35-45 DTE puts as the default
- Track FDA calendar for major ABBV pipeline decisions
- Time CCs around ex-dividend to capture the ~3.5% dividend
For real weekly wheel trades I run in my own account, the Omega Membership shares the trade plan. Or grab the free Starter Kit.
Ready to shadow real wheel trades?
The Omega Membership is the weekly trade plan I run in my own account — Sunday market prep, live calls, and the members' Discord.
See the membership → Free Starter KitFrequently asked questions
Is ABBV a good stock for the wheel strategy?
Yes — one of the best dividend + moderate IV combinations in mega-cap pharma. Pros: high ~3.5% dividend (among highest in wheel-viable pharma), moderate IV (~20-28%), deep options liquidity, successful post-Humira franchise (Skyrizi + Rinvoq), strong balance sheet. Cons: Skyrizi/Rinvoq concentration risk, FDA approval risk, drug pricing regulation, industry-standard litigation.
How much capital do I need to wheel ABBV?
One contract requires ~$18,000 at $180/share × 100. Practical minimum for responsible sizing (ABBV not exceeding 20% of wheel capital) is around $90-100k+ total capital.
How does ABBV's dividend affect the wheel?
ABBV pays ~$6.20/year per share (~3.4% yield) — approximately $155/quarter per contract when holding shares. One of the highest dividend yields in wheel-viable pharma. Time CCs to expire AFTER ex-dividend dates to capture dividend before potential assignment.
Is the Humira patent cliff still a concern for wheeling ABBV?
No, mostly resolved. Humira lost patent protection in 2023 and biosimilar erosion continues, but ABBV has successfully offset the decline with Skyrizi and Rinvoq (both growing rapidly). Wheelers who overweight the Humira concern miss opportunities. The remaining risk is Skyrizi/Rinvoq concentration.
ABBV vs MRK vs LLY for the wheel — which is better?
All three work; different profiles. ABBV: highest dividend (~3.5%), moderate IV, immunology-focused. MRK: solid dividend (~3.3%), oncology-focused with Keytruda 2028 patent cliff overhang. LLY: expensive ($780/share), lower dividend, high growth from GLP-1 drugs (Mounjaro/Zepbound). Pick based on account size and thesis preference.
Should I wheel ABBV through FDA decisions?
Reduce size 3-5 days before major PDUFA dates. Pipeline drug approvals/rejections can move ABBV 5-15% intraday. Track FDA calendar for major immunology, oncology, and next-gen decisions.
What are the biggest risks of wheeling ABBV?
Five specific ones: (1) Skyrizi/Rinvoq concentration — 30%+ of revenue in two drugs, (2) FDA approval risk on pipeline drugs, (3) drug pricing regulation under Inflation Reduction Act, (4) product liability litigation (industry standard), (5) continued Humira biosimilar erosion.
When should I skip wheeling ABBV?
Four situations: (1) 3-5 days before major FDA decisions on immunology/oncology pipeline drugs, (2) 7-10 days before earnings, (3) during major competitor drug approvals threatening Skyrizi/Rinvoq franchise, (4) if you already have significant pharma exposure through LLY/MRK/PFE/JNJ (concentration risk).